These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 22987092)

  • 1. Drug development for chronic cancers: time to think differently?
    Spriggs DR
    J Clin Oncol; 2012 Nov; 30(31):3779-80. PubMed ID: 22987092
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical trials of palliative chemotherapy in platinum-resistant or -refractory ovarian cancer: time to think differently?
    Friedlander ML; Stockler MR; Butow P; King MT; McAlpine J; Tinker A; Ledermann JA
    J Clin Oncol; 2013 Jun; 31(18):2362. PubMed ID: 23669225
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to M.L. Friedlander et al.
    Colombo N
    J Clin Oncol; 2013 Jun; 31(18):2363. PubMed ID: 23930277
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply to M.L. Friedlander et al.
    Spriggs DR
    J Clin Oncol; 2013 Jun; 31(18):2363. PubMed ID: 23930276
    [No Abstract]   [Full Text] [Related]  

  • 5. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
    Colombo N; Kutarska E; Dimopoulos M; Bae DS; Rzepka-Gorska I; Bidzinski M; Scambia G; Engelholm SA; Joly F; Weber D; El-Hashimy M; Li J; Souami F; Wing P; Engelholm S; Bamias A; Schwartz P
    J Clin Oncol; 2012 Nov; 30(31):3841-7. PubMed ID: 22987083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
    del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T
    Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study.
    Thaker PH; Brady WE; Lankes HA; Odunsi K; Bradley WH; Moore KN; Muller CY; Anwer K; Schilder RJ; Alvarez RD; Fracasso PM
    Gynecol Oncol; 2017 Nov; 147(2):283-290. PubMed ID: 28802766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controversy in treatment of advanced ovarian cancer.
    Scambia G; Salutari V; Amadio G
    Lancet Oncol; 2013 Sep; 14(10):920-1. PubMed ID: 23993374
    [No Abstract]   [Full Text] [Related]  

  • 9. Prolonged pegylated liposomal doxorubicin treatment for recurrent pelvic cancers: a feasibility study.
    Rabinovich A; Ramanakumar AV; Lau S; Gotlieb WH
    Acta Obstet Gynecol Scand; 2015 Jul; 94(7):776-780. PubMed ID: 25923364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
    Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
    BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary surgery or neoadjuvant chemotherapy in ovarian cancer: what is the value of comparing apples with oranges?
    Vergote I; Leunen K; Amant F
    Gynecol Oncol; 2012 Jan; 124(1):1-2. PubMed ID: 22153125
    [No Abstract]   [Full Text] [Related]  

  • 12. The Safety of Pegylated Liposomal Doxorubicin Plus Irinotecan in Recurrent Ovarian Cancer Patients: A Phase I Trial.
    Miyahara D; Ueda T; Katsuda T; Maehara M; Fukagawa S; Miyata K; Nam SO; Kondo H; Miyamoto S
    Anticancer Res; 2015 Aug; 35(8):4521-5. PubMed ID: 26168496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent epithelial ovarian cancer: an update on treatment.
    Foley OW; Rauh-Hain JA; del Carmen MG
    Oncology (Williston Park); 2013 Apr; 27(4):288-94, 298. PubMed ID: 23781692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers.
    Martin JY; Urban RR; Liao JB; Goff BA
    J Gynecol Oncol; 2016 Sep; 27(5):e47. PubMed ID: 27329195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes with single agent LIPO-DOX in platinum-resistant ovarian and fallopian tube cancers and primary peritoneal adenocarcinoma - Chiang Mai University Hospital experience.
    Suprasert P; Manopunya M; Cheewakriangkrai C
    Asian Pac J Cancer Prev; 2014; 15(3):1145-8. PubMed ID: 24606432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous oral cyclophosphamide as salvage or maintenance therapy in ovarian, primary peritoneal, and fallopian tube cancers: A retrospective, single institute study.
    Wong CN; Wong CN; Liu FS
    Taiwan J Obstet Gynecol; 2017 Jun; 56(3):302-305. PubMed ID: 28600037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: a Phase II Study of the Japanese Gynecologic Oncology Group.
    Katsumata N; Fujiwara Y; Kamura T; Nakanishi T; Hatae M; Aoki D; Tanaka K; Tsuda H; Kamiura S; Takehara K; Sugiyama T; Kigawa J; Fujiwara K; Ochiai K; Ishida R; Inagaki M; Noda K
    Jpn J Clin Oncol; 2008 Nov; 38(11):777-85. PubMed ID: 18927230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review.
    Roque DM; Ratner ES; Silasi DA; Azodi M; Rutherford TJ; Schwartz PE; Nelson WK; Santin AD
    Gynecol Oncol; 2015 Jun; 137(3):392-400. PubMed ID: 25792179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
    Gold MA; Brady WE; Lankes HA; Rose PG; Kelley JL; De Geest K; Crispens MA; Resnick KE; Howell SB
    Gynecol Oncol; 2012 Jun; 125(3):635-9. PubMed ID: 22446624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer.
    Webber K; Friedlander M
    Best Pract Res Clin Obstet Gynaecol; 2017 May; 41():126-138. PubMed ID: 28027849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.